Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Exploring GE HealthCare Technologies – A Brief Analysis

Is it worth buying GE HealthCare Technologies stock at a price of $69.78? If this question is on your mind, make sure to check out the fundamentals of this Medical Electronics Large-Cap company:

  • GE HealthCare Technologies has logged a -9.6% 52 week change, compared to 10.0% for the S&P 500

  • GEHC has an average analyst rating of buy and is -21.82% away from its mean target price of $89.25 per share

  • Its trailing earnings per share (EPS) is $4.34, which brings its trailing Price to Earnings (P/E) ratio to 16.1. The Health Care sector's average P/E ratio is 22.94

  • The company's forward earnings per share (EPS) is $4.67 and its forward P/E ratio is 14.9

  • The company has a Price to Book (P/B) ratio of 3.48 in contrast to the Health Care sector's average P/B ratio is 3.19

  • The current ratio is currently 1.0, which consists in its liquid assets divided by any liabilities due within in the next 12 months

  • GEHC has reported YOY quarterly earnings growth of 51.9% and gross profit margins of 0.4%

  • The company's free cash flow for the last fiscal year was $512.0 Million and the average free cash flow growth rate is -33.1%

  • GE HealthCare Technologies's revenues have an average growth rate of 3.1% with operating expenses growing at 7.3%. The company's current operating margins stand at 13.3%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS